Company: BIAF
Filing Date: 2025-04-15
Form Type: PRE 14A
Source: 0001641172-25-004857
Chunk: 4

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-04-15
Form: PRE 14A
Chunk 4
---
 2024 Annual Report
to Stockholders on or about April [●], 2025.

Voting Matters and the Board’s Recommendation

| Agenda Item                                                                                                                                                                                                                                                                                                              
 Election                                                                                                                                                                                                                                                                                                                 
 of seven directors                                                                                                                                                                                                                                                                                                       
 Ratification of WithumSmith+Brown, PC as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025                                                                                                                                                                        |     | Board Vote                
 Recommendation            
 FOR each Director Nominee 
 FOR                       |     | Page Reference 
 [●]            
 [●]            |
|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|:----|:--------------------------|:----|:---------------|
| Approval                                                                                                                                                                                                                                                                                                                 
 of a reverse stock split with respect to the Company’s issued and outstanding shares of common stock, par value $0.007 per                                                                                                                                                                                               
 share (“Common Stock”), at a ratio of 1-for-2 to 1-for-25 (the “Reverse Stock Split                                                                                                                                                                                                                                      
 Proposal”)                                                                                                                                                                                                                                                                                                               |     | FOR                       |     | [●]            |
| Approval of the issuance of up to an aggregate of 2,926,166 shares of our common stock upon the exercise of our common stock purchase warrants issued in connection with our private placement offering that closed on February 26, 2025 (the “Warrant Exercise Proposal”)                                               |     | FOR                       |     | [●]            |
| Approval of an adjournment of the Annual Meeting to a later date, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of the Reverse Stock Split Proposal or the Warrant Exercise Proposal |     | FOR                       |     | [●]            |

In addition to these matters, stockholders may be
asked to vote on such other business as may properly come before the Annual Meeting.

Even if you plan to attend the Annual Meeting, please vote in advance so that your vote will be counted if you later decide not to attend the Annual Meeting.

| 1 |

<div align='center'>QUESTIONS AND ANSWERS ABOUT

THE PROXY MATERIALS AND THE ANNUAL MEETING</div>

Who is soliciting my vote?

The Board of Directors
of bioAffinity Technologies, Inc. is soliciting your proxy to be used at the Annual Meeting.

Why did I receive a one-page Notice in the mail regarding the internet availability of proxy materials this year instead of a full set of proxy